↓ Skip to main content

Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese…

Overview of attention for article published in Orphanet Journal of Rare Diseases, July 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

policy
1 policy source
twitter
1 X user

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
54 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)
Published in
Orphanet Journal of Rare Diseases, July 2014
DOI 10.1186/s13023-014-0111-y
Pubmed ID
Authors

Hao-Chuan Liu, Hsiang-Yu Lin, Chia-Feng Yang, Hsuan-Chieh Liao, Ting-Rong Hsu, Chiao-Wei Lo, Fu-Pang Chang, Chun-Kai Huang, Yung-Hsiu Lu, Shuan-Pei Lin, Wen-Chung Yu, Dau-Ming Niu

Abstract

In Taiwan, DNA-based newborn screening showed a surprisingly high incidence (1/875 in males and 1/399 in females) of a cardiac Fabry mutation (IVS4 + 919G > A). However, the natural course, long-term treatment outcomes and suitable biomarkers for monitoring the therapeutic outcomes of these patients are largely unknown.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 54 100%

Demographic breakdown

Readers by professional status Count As %
Other 7 13%
Researcher 7 13%
Student > Master 7 13%
Student > Ph. D. Student 5 9%
Student > Bachelor 4 7%
Other 13 24%
Unknown 11 20%
Readers by discipline Count As %
Medicine and Dentistry 18 33%
Biochemistry, Genetics and Molecular Biology 8 15%
Agricultural and Biological Sciences 8 15%
Neuroscience 2 4%
Immunology and Microbiology 1 2%
Other 3 6%
Unknown 14 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2018.
All research outputs
#6,992,485
of 22,919,505 outputs
Outputs from Orphanet Journal of Rare Diseases
#996
of 2,630 outputs
Outputs of similar age
#66,418
of 228,852 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#23
of 47 outputs
Altmetric has tracked 22,919,505 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 2,630 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.5. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,852 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.